# argenx: Observational study closed enrollment, 152 enrolled (Congenital Myasthenic Syndrome)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | argenx |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4 |
| NCT ID | NCT06078553 |
| Phase | Observational |
| Status | active not recruiting |
| Conditions | Congenital Myasthenic Syndrome |
| Target enrollment | 152 |
| Site countries | United States, Austria, Belgium, Brazil, Canada, France, Germany, Italy, Japan, Poland, Spain, United Kingdom |
| Posted | 2023-10-12 |
| Planned start | 2024-02-13 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-05 |
| Last update posted | 2026-11-05 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 152 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06078553). Last refreshed: 2026-11-06T09:49:51.899Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.